Neil Hattangadi

Neil Hattangadi is a highly educated individual with a background in MD from Harvard Medical School, MSc from University of Oxford, and BSE from Duke University.

He has held key positions in various organizations, notably as the CEO at Cortica focusing on Advanced Neurological Therapies for Autism.

Prior to his current role, Neil served as an Executive Advisor at Entellus Medical, Inc., President & COO at Spirox, Inc., and in leadership roles in companies such as Philips, Volcano Corporation, and ev3 Inc./ FoxHollow Technologies.

His extensive professional journey also includes time as a Senior Analyst at Surveyor Capital / Citadel Investment Group, Analyst at Sigma/SAC Capital, Vice President at FoxHollow Clinical Affairs, Management Consultant at McKinsey & Company, and Research Fellow at Whitehead Genome Center/ Broad Institute.